GlassScriptPhysician profile
Jane Gwinn
NPI 1821089103
$611.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $14.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $285.67 | 2019-2020 | |
| Genzyme Corporation | $70.32 | 2019 | |
| Csl Behring | $70.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $65.29 | 2019 | |
| Kaleo, INC. | $40.89 | 2019 | |
| Grifols USA, LLC | $18.14 | 2019 | |
| Philips North America LLC | $16.56 | 2019 | |
| Alk-Abello, INC | $16.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.42 | 2019 | |
| Glaxosmithkline, LLC. | $12.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Gwinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.